ABPA Clinical Trial
Official title:
Cytokine Profile of Allergic Bronchopulmonary Aspergillosis and Its Relevance to Severity and Exacerbation.
The main aim of this study is to determine whether the levels of different inflammatory cytokines in the serum and BALF (bronchoalveolar lavage fluid) are relative to the severity and exacerbations of ABPA (allergic bronchopulmonary aspergillosis).
The study would record patients' medical data at baseline and follow them up for different period of time. Updated data would be recorded and blood( or BALF) of the patients would be drawn for tests or stored as whole blood or serum at -80℃ when patients visit the hospital. Then the cytokine (A panel set by the manufacturer) of the serum and BALF would be tested . The secretion ability of peripheral blood mononuclear cells would also be verified. The investigators would then analyze the data and see if any cytokine is relative to the exacerbation or other indicators of the severity of ABPA. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02853175 -
Lung MRI and Allergic Broncho-pulmonary Aspergillosis in Cystic Fibrosis
|
||
| Withdrawn |
NCT05903612 -
Allergic Bronchopulmonary Aspergillosis Prescreening Study
|
||
| Terminated |
NCT05667662 -
Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA
|
Phase 2 | |
| Withdrawn |
NCT04108962 -
Benralizumab in the Treatment of Patients With Severe Asthma With ABPA
|
Phase 4 |